Showing 171-180 of 9671 results for "".
Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inUnderstanding and Addressing the Impact of Plaque Psoriasis Among Patients with Skin of Color
https://practicaldermatology.com/topics/psoriasis/understanding-and-addressing-the-impact-of-plaque-psoriasis-among-patients-with-skin-of-color/23763/Patients, physicians, and others are joining together to elevate the level of care for patients with skin of color who develop psoriatic disease.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarshWhat Dermatologists Should Know About Advocacy
https://practicaldermatology.com/topics/practice-management/what-dermatologists-should-know-about-advocacy/23678/The specialty needs advocacy. Here’s why and how to get involved.DermWireTV: Updates from ASDS: EBDs, Injectables, Scars, DEI
https://practicaldermatology.com/topics/practice-management/dermwiretv-updates-from-asds-ebds-injectables-scars-dei/20029/The annual meeting of the American Society for Dermatology Surgery (ASDS) brings together top dermatologists to share their expertise. This year’s virtual meeting offered a look at a range of new and emerging treatments and some updates on existing options, including insights from Jeanine B. Downie,Optimizing Skin Exams with a Next-Gen Wireless Handheld Dermoscopy Solution
https://practicaldermatology.com/topics/practice-management/optimizing-skin-exams-with-a-next-gen-wireless-handheld-dermoscopy-solution/23571/The Barco Demetra Dermoscopy solution combines features of analog and digital imaging to support clinical decision-making for a range of skin presentations.DermWireTV: Soliton's Resonic Launch, Natroba for Scabies, UV Safety
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-solitons-resonic-launch-natroba-for-scabies-uv-safety/19938/Skin Cancer awareness month provides an opportunity for dermatologists to double down on patient outreach as the AAD launches the “Skin Cancer, Take a Hike” steps challenge. Soliton’s Rapid Acoustic Pulse Device launches under the name Resonic. Natroba (Spinosad) Topical Suspension from ParaPRO is nManaging Advanced Skin Cancers
https://practicaldermatology.com/conferences/aad-2021/managing-advanced-skin-cancers/19920/Treatment of advanced NMSC can be a challenge, but therapeutic options continue to expand. Todd Schlesinger, MD discusses real-world use of hedgehog inhibitors—including modified regimens and adjuvant use—and PD-1 inhibitors for advanced disease.